Public company intelligence preview
XBIOTECH INC
4 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $2.2M average total compensation across covered insiders.
Governance movement
Public aggregate: 4 governance events in the last year.
Institutional ownership
Public aggregate: 42 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
XBiotech Inc. is a Healthcare sector, Biotechnology company developing “True Human” monoclonal antibodies derived from human donors rather than animals. Its core programs target IL-1 alpha and include candidates in oncology, rheumatology, stroke/reperfusion injury, and infectious diseases such as MRSA, C. difficile, shingles, and influenza. The company is still pre-revenue / clinical-stage, with no near-term product sales expected until one of its candidates achieves regulatory approval and commercialization. It operates from a substantial research and manufacturing campus in Austin, Texas, and combines discovery, development, and manufacturing internally, which is an important part of its business model.
Executive Compensation Practices
Compensation at XBiotech appears to be heavily influenced by development-stage milestones, cash preservation, and equity incentives, which is typical for Biotechnology companies. The filing summaries show that R&D and G&A costs were materially affected by salary, severance, bonus expense, and stock-based compensation, including charges tied to former CEO John Simard and new option grants. For a company without revenue, executive pay is likely less tied to sales growth and more connected to pipeline progress, trial readiness, regulatory steps, manufacturing capabilities, and liquidity management. Stock compensation is especially relevant here because it aligns management with long-term value creation, but it can also create volatility in reported expenses when grants are made or leadership changes occur.
Insider Trading Considerations
Insider trading activity in XBiotech should be viewed through the lens of a small, clinical-stage biotech with binary event risk. With no active clinical trials in parts of 2025 and future value dependent on FDA interactions and trial outcomes, insiders may trade around trial initiation, data readouts, regulatory updates, licensing decisions, or capital allocation events. The company’s significant cash balance and history of share repurchases and dividends may also make insider activity more sensitive to perceptions of cash deployment versus pipeline investment. In Biotechnology, insider sales are often interpreted cautiously because share prices can move sharply on clinical or regulatory news, while insider buys may signal confidence in pipeline progress, trial timing, or undervaluation.
Unlock the full XBIT insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.